

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-24 (canceled).

25 (previously presented). A purified collagenase inhibitor protein, said protein consisting essentially of an amino acid sequence selected from among the following:

a) amino acid sequence SEQ ID NO: 2; or

b) the amino acid sequence of a) or of SEQ ID NO: 1, further having a Met at position -1; or

c) the amino acid sequence of a) or of SEQ ID NO: 1, further having a leader sequence at the N-terminal, -1 position, wherein said leader sequence consists essentially of the following amino acid sequence from positions -38 to -1:

Gly His Arg Arg Arg Ser Ser Ala Gln Arg Asp Thr Arg Glu Pro Thr Met Ala Pro Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala Asp Ser Pro Ser Arg Ala (SEQ ID NO: 3);

or

d) the amino acid sequence of a) or of SEQ ID NO: 1, further having a leader sequence at the N-terminal, -1 position, wherein said leader sequence consists essentially of the following amino acid sequence from positions -22 to -1: Met Ala Pro Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala Asp Ser Pro Ser Arg Ala (SEQ ID NO: 4).

26 (canceled).

27 (withdrawn). A recombinant plasmid or viral vector, wherein said recombinant plasmid or viral vector comprises DNA encoding a collagenase inhibitor protein, wherein

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

said protein consists essentially of an amino acid sequence selected from among the following:

- a) amino acid sequence SEQ ID NO: 1; or
- b) amino acid sequence SEQ ID NO: 2; or
- c) the amino acid sequences of a) or b), further having a Met at position -1;

or

d) the amino acid sequence of a) or b), further having a leader sequence at the N-terminal, -1 position, wherein said leader sequence consists essentially of the following amino acid sequence from positions -38 to -1:

Gly His Arg Arg Arg Ser Ser Ala Gln Arg Asp Thr Arg Glu Pro Thr  
Met Ala Pro Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala  
Asp Ser Pro Ser Arg Ala (SEQ ID NO: 3); or

e) the amino acid sequence of a) or b) further having a leader sequence at the N-terminal, -1 position, wherein said leader sequence consists essentially of the following amino acid sequence from positions -22 to -1: Met Ala Pro Phe Asp Pro Trp  
Leu Leu His Pro Val Val Ala Val Ala Asp Ser Pro Ser Arg Ala (SEQ ID NO: 4).

28 (withdrawn). A recombinant plasmid or viral vector, wherein said recombinant plasmid or viral vector comprises DNA encoding a collagenase inhibitor protein, wherein said protein comprises SEQ ID NO: 1, and wherein SEQ ID NO: 1 further comprises a glycine (Gly) at position 28, a threonine (Thr) at position 43, a glycine (Gly) at position 48, an alanine (Ala) at position 111, a glutamine (Glu) at position 125, and a threonine (Thr) at position 128, and optionally a methionine (Met) is at position -1.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

29 (withdrawn). A eukaryotic or prokaryotic host cell transformed or transfected with the recombinant plasmid or viral vector of claim 27.

30 (withdrawn). A eukaryotic or prokaryotic host cell transformed or transfected with the recombinant plasmid or viral vector of claim 28.

31 (withdrawn). A process for producing a collagenase inhibitor protein, comprising:

a) culturing the host cell of claim 29, under conditions wherein said host cell expresses said collagenase inhibitor; and

b) collecting said expressed collagenase inhibitor.

32. (New) A process for producing a collagenase inhibitor protein, comprising:

a) culturing the host cell of claim 30, under conditions wherein said host cell expresses said collagenase inhibitor; and

b) collecting said expressed collagenase inhibitor.

33 (withdrawn). A recombinant-DNA method for microbial production of a collagenase inhibitor comprising:

(a) culturing a host microorganism under conditions where said collagenase inhibitor is expressed, said host microorganism containing the vector pUC9-F5/237P10, said vector comprising a nucleotide sequence encoding a collagenase inhibitor;

(b) culturing said host microorganism under conditions appropriate for expression of said collagenase inhibitor; and

(c) harvesting said collagenase inhibitor.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

34 (withdrawn). The method of claim 33, wherein said host microorganism is a bacterium.

35 (withdrawn). The method of claim 34, wherein said bacterium is a member of the genus *Bacillus*.

36 (withdrawn). The method of claim 35, wherein said bacterium is *Bacillus subtilis*.

37 (withdrawn). The method of claim 34, wherein said bacterium is *Escherichia coli*.

38 (withdrawn). The method of claim 34, wherein said bacterium is a member of the genus *Pseudomonas*.

39 (withdrawn). The method of claim 38, wherein said bacterium is *Pseudomonas aeruginosa*.

40 (withdrawn). The method of claim 33, wherein said host microorganism is a yeast.

41 (withdrawn). The method of claim 40, wherein said yeast is *Saccharomyces cerevisiae*.

42 (withdrawn). A host microorganism comprising the vector of claim 27 or 28.43 (canceled).

43. (canceled).

44 (new). A purified collagenase inhibitor protein, said protein consisting essentially of an amino acid sequence selected from:

a) amino acid sequence SEQ ID NO: 1 or amino acid sequence SEQ ID NO: 2, wherein a glutamine (Glu) at position 28 is substituted by an asparagine;

b) amino acid sequence SEQ ID NO: 1 or amino acid sequence SEQ ID NO: 2, wherein a threonine (Thr) at position 43 is substituted by a methionine;

c) amino acid sequence SEQ ID NO: 1 or amino acid sequence SEQ ID NO: 2, wherein a glycine (Gly) at position 48 is substituted by a glutamine;

d) amino acid sequence of SEQ ID NO: 1, wherein an alanine (Ala) at position 111 is substituted by an arginine;

e) amino acid sequence of SEQ ID NO: 1, wherein a glutamine (Glu) at position 125 is substituted by a cysteine;

f) amino acid sequence of SEQ ID NO: 1, wherein a threonine (Thr) at position 128 is substituted by a phenylalanine;

g) the amino acid sequence of (a), (b), (c), (d), (e), or (f), further having a Met at position -1;

h) the amino acid sequence of (a), (b), (c), (d), (e), or (f), further having a leader sequence at the N-terminal, -1 position, wherein said leader sequence consists essentially of the following amino acid sequence from positions -38 to -1:

Gly His Arg Arg Arg Ser Ser Ala Gln Arg Asp Thr Arg Glu Pro Thr Met Ala

Pro Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala Asp Ser Pro Ser

Arg Ala (SEQ ID NO: 3); and

i) the amino acid sequence of (a), (b), (c), (d), (e), or (f), further having a leader sequence at the N-terminal, -1 position, wherein said leader sequence consists essentially of the following amino acid sequence from positions -22 to -1:

Met Ala Pro Phe Asp Pro Trp Leu Leu His Pro Val Val Ala Val Ala Asp Ser

Pro Ser Arg Ala (SEQ ID NO: 4).

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com